Blood cancers

HSCT still wins over novel agents for multiple myeloma

Highly active novel agents for multiple myeloma aren’t going to bump autologous haematopoietic stem-cell transplantation (aHSCT) from its position as gold standard intensification treatment – yet. An open-label, phase 3 clinical trial of 1,197 adults with newly diagnosed multiple myeloma and fit for high dose, myeloablative chemotherapy randomised patients to single or double aHSCT or ...

Already a member?

Login to keep reading.

© 2021 the limbic